DYN ▼ -28.5% - Dyne Therapeutics, Inc. $DYN - Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings Dyne Therapeutics fell 28.5% today following an announcement that it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of Z-Basivarsen for myotonic dystrophy at upcoming medical meetings. The sharp decline suggests investors may have interpreted the timing or scope of the data presentation as disappointing relative to prior expectations, though the headline does not specify the nature of the results themselves. 08-SEP-2026 07:51 AM ET